Posted inMarket
Vaxcyte Strengthens Leadership Team and Accelerates Clinical Trial Timeline
Vaxcyte appoints two new executive leaders and narrows the anticipated trial timeline for its key pneumococcal conjugate vaccine candidate.
Posted inMarket
Baird Increases Climb Bio Stock Price Target Following Trial Data
Financial firm Baird has raised its price target for Climb Bio stock to $25 following recent clinical trial data updates.
Posted inEmerging Market
Eli Lilly Targets 2027 Approval for Next-Generation Triple-Agonist Obesity Drug Retatrutide
Eli Lilly plans to seek approval for its next-generation obesity drug retatrutide by 2027 following highly successful late-stage clinical trials.
Posted inBusiness Insights
Suven’s High-Stakes Neuroscience Bet Enters Decisive Late-Stage Clinical Trials
Suven Life Sciences, a leading Indian biopharmaceutical innovator, has entered the final stretch of clinical development for its ambitious central nervous system (CNS) pipeline, positioning itself to address some of…
Posted inEmerging Market
UniQure to Seek FDA Approval for Huntington’s Disease Gene Therapy Following Regulatory Dispute
UniQure is pursuing FDA approval for its Huntington's disease gene therapy AMT-130, navigating past regulatory hurdles for this promising treatment.
